{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015993","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.599723+00:00","generated_at":"2026-06-15T16:13:17.411771+00:00","sec_items":["2.02","3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ocugen receives Nasdaq bid price deficiency notice and reports Q1 net loss of $0.07 per share","bullets":["Nasdaq notified Ocugen on May 1 that its stock closed below $1.00 for 30 consecutive days; 180-day cure period until Oct 30, 2023.","Cash and investments $76.7M at March 31, 2023, down from $90.9M at Dec 31, 2022; funding expected into Q1 2024.","Net loss per share $0.07 in Q1 2023 vs $0.09 in Q1 2022; total operating expenses $17.8M.","OCU400 Phase 1/2 shows positive preliminary efficacy/safety; FDA approved pediatric enrollment; Phase 3 trial planned late 2023.","COVAXIN development in North America discontinued; shift to inhaled mucosal vaccine platform (flu and COVID-19)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015993","json":"https://secwatch.observer/filing/0001628280-23-015993.json","markdown":"https://secwatch.observer/filing/0001628280-23-015993.md","text":"https://secwatch.observer/filing/0001628280-23-015993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/0001628280-23-015993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/ocgn-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:13:17.411771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b528b3a42e19dbf7d219657a3a9fcb878b4e59c5","claim":"Ocugen, Inc. reported the three months ended March 31, 2023 results: EPS $0.07 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.07 net loss per common share for the three months ended March 31, 2023 compared to a $0.09 net loss per common share for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/0001628280-23-015993-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"EPS","value":"$0.07 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}